{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:59:50Z","timestamp":1787313590139,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10-12","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSC BIOCAD","award":["BCD-089-4\/CORONA"],"award-info":[{"award-number":["BCD-089-4\/CORONA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective and design<\/jats:title>\n                    <jats:p>The aim of this double-blind, placebo-controlled, phase III CORONA clinical trial was to evaluate the efficacy and safety of IL-6 receptor inhibitor levilimab (LVL) in subjects with severe COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects<\/jats:title>\n                    <jats:p>The study included 217 patients. The eligible were men and non-pregnant women aged 18\u00a0years or older, hospitalized for severe COVID-19 pneumonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Treatment<\/jats:title>\n                    <jats:p>206 subjects were randomized (1:1) to receive single subcutaneous administration of LVL 324\u00a0mg or placebo, both in combination with standard of care (SOC). 204 patients received allocated therapy. After the LVL\/placebo administration in case of deterioration of symptoms, the investigator could perform a single open-label LVL 324\u00a0mg administration as the rescue therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The primary efficacy endpoint was the proportion of patients with sustained clinical improvement on the 7-category ordinal scale on Day 14. All efficacy data obtained after rescue therapy administration were considered missing. For primary efficacy analysis, all subjects with missing data were considered non-responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      63.1% and 42.7% of patients in the LVL and in the placebo groups, respectively, achieved sustained clinical improvement on Day 14 (\n                      <jats:italic>P\u2009<\/jats:italic>\n                      =\u2009.0017). The frequency of adverse drug reactions was comparable between the groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with radiologically confirmed SARS-CoV-2 pneumonia, requiring or not oxygen therapy (but not ventilation) with no signs of other active infection administration of LVL\u2009+\u2009SOC results in an increase of sustained clinical improvement rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trail registration<\/jats:title>\n                    <jats:p>The trial is registered at the US National Institutes of Health (ClinicalTrials.gov; NCT04397562).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00011-021-01507-5","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T07:03:30Z","timestamp":1632899010000},"page":"1233-1246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study"],"prefix":"10.1007","volume":"70","clinical-trial-number":[{"clinical-trial-number":"nct04397562","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8830-7231","authenticated-orcid":false,"given":"Nikita V.","family":"Lomakin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-1608","authenticated-orcid":false,"given":"Bulat A.","family":"Bakirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5166-3280","authenticated-orcid":false,"given":"Denis N.","family":"Protsenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-2051","authenticated-orcid":false,"given":"Vadim I.","family":"Mazurov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6550-7975","authenticated-orcid":false,"given":"Gaziyavdibir H.","family":"Musaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7817-3847","authenticated-orcid":false,"given":"Olga M.","family":"Moiseeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6217-2818","authenticated-orcid":false,"given":"Elena S.","family":"Pasechnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1570-2748","authenticated-orcid":false,"given":"Vladimir V.","family":"Popov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2615-7167","authenticated-orcid":false,"given":"Elena A.","family":"Smolyarchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3233-4369","authenticated-orcid":false,"given":"Ivan G.","family":"Gordeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2870-3301","authenticated-orcid":false,"given":"Mikhail Yu","family":"Gilyarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5083-6637","authenticated-orcid":false,"given":"Darya S.","family":"Fomina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9582-7921","authenticated-orcid":false,"given":"Anton I.","family":"Seleznev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5463-1022","authenticated-orcid":false,"given":"Yulia N.","family":"Linkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6759-673X","authenticated-orcid":false,"given":"Ekaterina A.","family":"Dokukina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-6911","authenticated-orcid":false,"given":"Anna V.","family":"Eremeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9790-8207","authenticated-orcid":false,"given":"Polina S.","family":"Pukhtinskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7755-7526","authenticated-orcid":false,"given":"Maria A.","family":"Morozova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8499-2232","authenticated-orcid":false,"given":"Arina V.","family":"Zinkina-Orikhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2884-1568","authenticated-orcid":false,"given":"Anton A.","family":"Lutckii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"issue":"7","key":"1507_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.cmi.2020.04.023","volume":"26","author":"M Cevik","year":"2020","unstructured":"Cevik M, Bamford CGG, Ho A. COVID-19 pandemic-a focused review for clinicians. Clin Microbiol Infect. 2020;26(7):842\u20137.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"1507_CR2","doi-asserted-by":"publisher","first-page":"2000607","DOI":"10.1183\/13993003.00607-2020","volume":"55","author":"RJ Mason","year":"2020","unstructured":"Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607. https:\/\/doi.org\/10.1183\/13993003.00607-2020.","journal-title":"Eur Respir J"},{"key":"1507_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s41232-020-00146-3","volume":"40","author":"S Hojyo","year":"2020","unstructured":"Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40:37.","journal-title":"Inflamm Regen"},{"issue":"10","key":"1507_CR4","doi-asserted-by":"publisher","first-page":"e592","DOI":"10.1016\/S2665-9913(20)30313-1","volume":"2","author":"B Furlow","year":"2020","unstructured":"Furlow B. COVACTA trial raises questions about tocilizumab\u2019s benefit in COVID-19. Lancet Rheumatol. 2020;2(10):e592.","journal-title":"Lancet Rheumatol."},{"issue":"10","key":"1507_CR5","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","volume":"26","author":"AG Laing","year":"2020","unstructured":"Laing AG, Lorenc A, Del Molino Del Barrio I, Das A, Fish M, Monin L, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020;26(10):1623\u201335.","journal-title":"Nat Med"},{"issue":"12","key":"1507_CR6","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1080\/13543784.2020.1840549","volume":"29","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Price CC. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. Expert Opin Investig Drugs. 2020;29(12):1407\u201312.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"1507_CR7","first-page":"884","volume":"77","author":"P Khlyabova","year":"2018","unstructured":"Khlyabova P, Eremeeva A, Lutckii A, Dokukina E, Chernyaeva E, Ivanov R. SAT0040 Safety, tolerability, pharmacokinetics and pharmacodynamics of bcd-089, novel monoclonal anti-il-6 receptor antibody: results from the first-in-human single dose escalation study in healthy volunteers. Ann Rheum Dis. 2018;77(2):884\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1507_CR8","first-page":"637","volume":"79","author":"V Mazurov","year":"2020","unstructured":"Mazurov V, Zotkin E, Ilivanova E, Kropotina T, Plaksina T, Nesmeyanova O, et al. FRI0114 efficacy of levilimab, novel monoclonal anti-il-6 receptor antibody, in combination with methotrexate in patients with rheumatoid arthritis: 1\u00a0year results of phase 2 AURORA study. Ann Rheum Dis. 2020;79(1):637\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1507_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rmv.2141","volume":"30","author":"EA Coomes","year":"2020","unstructured":"Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: a systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1\u20139.","journal-title":"Rev Med Virol"},{"issue":"19","key":"1507_CR10","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787\u201399.","journal-title":"N Engl J Med"},{"issue":"10236","key":"1507_CR11","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569\u201378.","journal-title":"Lancet"},{"issue":"8","key":"1507_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.7326\/M20-4044","volume":"173","author":"ZR McCaw","year":"2020","unstructured":"McCaw ZR, Tian L, Vassy JL, Ritchie CS, Lee CC, Kim DH, et al. How to quantify and interpret treatment effects in comparative clinical studies of COVID-19. Ann Intern Med. 2020;173(8):632\u20137.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1507_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20\u201330.","journal-title":"N Engl J Med"},{"issue":"24","key":"1507_CR14","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","volume":"383","author":"JH Stone","year":"2020","unstructured":"Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333\u201344.","journal-title":"N Engl J Med"},{"key":"1507_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejim.2020.05.009","volume":"76","author":"R Capra","year":"2020","unstructured":"Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020;76:31\u20135.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"1507_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","volume":"181","author":"O Hermine","year":"2021","unstructured":"Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32\u201340.","journal-title":"JAMA Intern Med"},{"issue":"16","key":"1507_CR17","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"R-C Investigators","year":"2021","unstructured":"Investigators R-C, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N Engl J Med. 2021;384(16):1491\u2013502.","journal-title":"N Engl J Med"},{"issue":"16","key":"1507_CR18","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","volume":"384","author":"IO Rosas","year":"2021","unstructured":"Rosas IO, Brau N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503\u201316.","journal-title":"N Engl J Med"},{"issue":"2","key":"1507_CR19","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1093\/cid\/ciaa954","volume":"73","author":"EC Somers","year":"2021","unstructured":"Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2021;73(2):e445\u201354.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1507_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.cmi.2020.09.021","volume":"27","author":"J Martinez-Sanz","year":"2021","unstructured":"Martinez-Sanz J, Muriel A, Ron R, Herrera S, Perez-Molina JA, Moreno S, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study. Clin Microbiol Infect. 2021;27(2):238\u201343.","journal-title":"Clin Microbiol Infect"},{"issue":"10285","key":"1507_CR21","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"Group RC","year":"2021","unstructured":"Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637\u201345.","journal-title":"Lancet"},{"key":"1507_CR22","doi-asserted-by":"publisher","unstructured":"Zeraatkar D, Cusano E, Martinez JPD, Qasim A, Mangala SO, Kum E, et al. (2021) Tocilizumab and sarilumab alone or in combination with corticosteroids for COVID-19: a systematic review and network meta-analysis. medRxiv. 2021.07.05.21259867. https:\/\/doi.org\/10.1101\/2021.07.05.21259867","DOI":"10.1101\/2021.07.05.21259867"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-021-01507-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-021-01507-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-021-01507-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T09:04:07Z","timestamp":1636275847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-021-01507-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":22,"journal-issue":{"issue":"10-12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1507"],"URL":"https:\/\/doi.org\/10.1007\/s00011-021-01507-5","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"11 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research leading to these results received funding from BIOCAD under Grant Agreement No BCD-089-4\/CORONA. Authors Nikita V. Lomakin, Bulat A. Bakirov, Denis N. Protsenko, Vadim I. Mazurov, Gaziyavdibir H. Musaev, Olga M. Moiseeva, Elena S. Pasechnik, Vladimir V. Popov, Elena A. Smolyarchuk, Ivan G. Gordeev, Darya S. Fomina have no conflicts of interest to declare that are relevant to the content of this article. Author Mikhail Yu. Gilyarov received a speaking fee from Boehringer Ingelheim, Bayer, Pfizer \u0438 Servier. Authors Anton I. Seleznev, Yulia N. Linkova, Ekaterina A. Dokukina, Polina S. Pukhtinskaia, Anna V. Eremeeva, Maria A. Morozova, Arina V. Zinkina-Orikhan and Anton A. Lutckii, are JSC BIOCAD employees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki of 1964, and its later amendments and was approved by the Central Regulatory Authorities of the Russian Federation (Authorization by the Ministry of Healthcare of the Russian Federation No. 176 of April 22, 2020; Extract from minutes of Ethics Council of Ministry of Health of The Russian Federation No.216, dated 21th of April, 2020) and Ethical Review Boards of each of the participating sites.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"There is no identifiable information in the manuscript. Patients signed informed consent which included information about publishing the analyzed data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}